Premium
Association between pioglitazone use and head and neck cancer: Population‐based case‐control study
Author(s) -
Yang TzongHann,
Xirasagar Sudha,
Cheng YenFu,
Wu ChuanSong,
Kao YiWei,
Shia BenChang,
Lin HerngChing
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26046
Subject(s) - pioglitazone , medicine , odds ratio , logistic regression , head and neck cancer , propensity score matching , cancer , case control study , bivariate analysis , oncology , diabetes mellitus , type 2 diabetes , endocrinology , statistics , mathematics
Background This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. Methods Data for this case‐control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. Results Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P < .001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02‐1.10) among cases relative to controls. Conclusions Prior pioglitazone use was associated with oral cavity cancer.